Kidney Diseases Stem Cell Therapy Development

Kidney disease encompasses a range of disorders affecting the kidneys' structure and function, including chronic kidney disease (CKD), acute kidney injury (AKI), and certain genetic kidney diseases. Stem cell therapy offers a potential avenue to repair or regenerate damaged kidney tissue. CD BioSciences offers stem cell therapy development services for kidney diseases, based on out advanced technology and professional team.

Fig 1. Kidney

Introduction into Kidney Diseases

Kidney diseases represent a significant health challenge globally, affecting millions of individuals and often leading to severe complications if left untreated. The kidneys play a vital role in filtering waste products and excess fluids from the blood, maintaining electrolyte balance, and regulating blood pressure. When kidney function is compromised due to disease or injury, it can result in various kidney disorders, such as chronic kidney disease (CKD), acute kidney injury (AKI), and end-stage renal disease (ESRD).

Stem Cell Therapy for Kidney Diseases

Stem cell therapy is a groundbreaking approach in regenerative medicine that holds significant potential for the treatment of kidney diseases. Stem cells, with their unique ability to differentiate into various cell types, offer several advantages for addressing kidney disorders: 1) Regeneration of Kidney Tissue; 2) Anti-Inflammatory Effects; 3) Immunomodulation; 4) Angiogenesis.

Fig 2. Mechanism of MSCs in the treatment of kidney diseases Mechanism of MSCs in the treatment of kidney diseases (Liu, et al., 2020)

The preferential transport of MSCs to sites of ischemia, hypoxia, and inflammatory response after injury plays a crucial role in the success of organ injury cell therapy. MSCs secrete a broad repertoire of cytokines, chemokines, and growth factors, including:

IL-6 and IL-11
Macrophage-colony stimulating factor (M-CSF)
Vascular endothelial growth factor (VEGF)
Granulocyte-colony stimulating factor (G-CSF)
Insulin-like growth factor (IGF)

Leukemia inhibitory factor (LIF)
Basic fibroblast growth factor (bFGF)
Monocyte-chemoattractant protein-1 (MCP-1)
Hepatocyte growth (HGF)

They contribute in renal protection by promoting proliferation of epithelial cells and angiogenesis, anti-apoptosis, anti-inflammatory, anti-fibrosis, and other signaling pathways. Followings are clinical trails of MSCs utilized in kidney disease treatment.

Condition or disease	Source	Main findings
AKI after cardiac surgery	Allogeneic BM-MSCs	MSC infusion was safe
		None of the patients developed postoperative AKI or subsequent loss of kidney function
		Protection against early and late post-surgery kidney function deterioration
		Reduction in length of hospital stay
		No significant difference between groups in 30-d all-cause mortality or dialysis
		No reduction in the time to recover kidney function
CKD	Autologous BM-MSCs	MSC infusion was safe and tolerated
		No significant changes in eGFR and SCr
	Autologous AD-MSCs	MSC infusion was safe and not associated with adverse effects
		Statistically significant improvement in urinary protein excretion but not in GFR
	Autologous CD34+ EPCs	MSC infusion was safe and tolerated
		No additional benefit from EPCs up to a follow-up period
		Significantly lower unfavourable clinical outcomes (dialysis or death) in treatment group
Diabetic nephropathy (type 2)	Allogeneic BM-MSCs	MSC infusion was safe and not associated with acute adverse events
		Stabilization and improvement in eGFR and mGFR
Atherosclerotic renovascular disease	Autologous AD-MSCs	MSC infusion was safe and well tolerated.
		Increment in cortical perfusion and renal blood flow
		Reduction in renal tissue hypoxia within poststenotic kidney
Refractory SLE	Allogeneic BM-MSCs	MSC infusion was safe and well-tolerated
		It improved disease activity and stabilized kidney function
		MSC infusion was safe
		It also reduced protein in the urine at 9- and 12-month follow-ups
LN (class III or IV)	Allogeneic UC-MSCs	No apparent additional effect over and above standard immunosuppression
Active and refractory LN	Allogeneic BM-MSCs or UC-MSCs	Significant improvement in proteinuria levels during the 1st month after treatment
		The ameliorations were sustained throughout the follow-up period
Kidney transplant	Autologous BM-MSCs	MSC infusion was safe and didn't harm kidney transplant survival
		It lowered the chances of kidney rejection
		It reduced the risk of infections and improved kidney function after 1 year
		It boosted the immune system's helpful T cells and controlled harmful memory T cells
		There were no major side effects in the long term

Our Services

CD BioSciences offers stem cell therapy development service for spinal cord injury based on our advanced technology and professional team. Our stem cell therapy development services are offered in kidney diseases included but not limited as follows:

Chronic Kidney Disease (CKD)
Acute Kidney Injury (AKI)
Polycystic Kidney Disease (PKD)
Glomerulonephritis

Diabetic Nephropathy
Lupus Nephritis
Hypertensive Nephropathy
Kidney Transplantation

As a pioneer in biotechnology, CD BioSciences has grown into one of the largest independent biotechnology companies in the world. CD BioSciences is committed to providing professional and efficient service to our customers around the world. If you are interested in our service, please contact us.

Reference

Liu, D., Cheng, F., Pan, S. et al. Stem cells: a potential treatment option for kidney diseases. Stem Cell Res Ther 11, 249 (2020).

For research use only, not for clinical use.